ROME--(EON: Enhanced Online News)--At Critical Diagnostics’ annual European Distributor-Partners Meeting held in Rome this week, the company unveiled its Aspect-LF™ ST2 test, a point-of-care version of the company's lab-based Presage® ST2 Assay. Aspect-LF will be made available throughout Europe and select Asia-Pacific countries later this year.
“not only predictive of hospitalization and death in patients with HF [heart failure] but also additive to natriuretic peptide levels in [its] prognostic value.”
Aspect-LF is a disposable cartridge, based on lateral flow technology that uses finger-stick whole blood for qualitatively measuring ST2. Results take approximately 20 minutes, enabling physicians to receive vital information on a patient’s heart failure disease status while still in the doctor’s office or clinic -- which can aid greatly in treatment decisions.
Worldwide, some 26 million people have been diagnosed with heart failure. At a time when deaths from coronary heart disease and stroke are declining on a relative basis, mortality from heart failure is increasing. Heart failure accounts for more hospitalizations than all forms of cancer, and the prognosis for heart failure is worse than cancer. According to the American Heart Association, as many as 20% of heart failure patients die within one year of diagnosis and half die within five years.
ST2 has been included in the new 2013 ACC/AHA update to the Guideline For Management of Heart Failure, receiving an “A,” the highest classification for the body of evidence supporting its recommendation as, “not only predictive of hospitalization and death in patients with HF [heart failure] but also additive to natriuretic peptide levels in [its] prognostic value.”
"Critical Diagnostics is committed to helping physicians improve and prolong the lives of the millions of people suffering from heart failure," said David Geliebter, CEO of Critical Diagnostics. "Aspect-LF is a fine example of how we are fulfilling that pledge, and is just one new creation in a lineup of innovative cardiac care diagnostic products slated to be released by the company over the next year."
As nearly 100 peer-reviewed published studies on more than 50,000 patients have demonstrated, ST2 has the highest prognostic value of any commercially available cardiac marker in predicting heart failure patient outcomes, including hospitalization, re-hospitalization and mortality, allowing for the identification of high-risk heart failure patients versus those at lower risk. Aspect-LF from Critical Diagnostics is the only commercially available rapid ST2 biomarker test in the world.
About Critical Diagnostics
Founded in 2004, Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. Critical Diagnostics has distribution partners for its Presage ST2 Assay in 45 countries, covering two-thirds of the world’s population.